Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Adding Lenalidomide to R-MiniCHOP Did Not Improve Survival
Key clinical point: The addition of lenalidomide to rituximab plus a reduced dose of CHOP chemotherapy regimen did not improve survival in patients with newly diagnosed diffuse large B-cell lymphoma who were at least 80 years old.
Major finding: The 2-year overall survival was 66% among patients receiving rituximab plus miniCHOP versus 65.7% for patients who added lenalidomide to that regimen (P = .98).
Study details: A phase 3 trial of 249 patients with newly diagnosed diffuse large B-cell lymphoma who were at least 80 years old.
Disclosures: Dr. Oberic reported disclosures related to Janssen, Roche, and Takeda.
Citation:
Oberic L et al. ASH 2019, Abstract 352.